United States — Food and Drug Administration & Pfizer
14 shared events · Importance 4 · Last updated Aug 25, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration>>> granted the expanded approval for HYMPAVZI, validating its efficacy and safety for a broader patient population. This action reflects the agency's role in regulating and approving pharmaceutical products in the United States>>>.
Pfizer: The expanded approval of HYMPAVZI by the United States — Food and Drug Administration>>> is a significant positive development for Pfizer>>>, enhancing its product portfolio and market reach in the hemophilia treatment space. This approval is expected to boost Pfizer>>>'s revenue and solidify its position as a leader in rare disease therapies.
Jun 08, 2026 · 7 articles
Regulatory
United States — Food and Drug Administration: The FDA accepted the application for Priority Review and will decide by Q4 2026.
Pfizer: Pfizer is the applicant seeking FDA approval for its drug combination; positive regulatory news may support revenue growth.
Jul 22, 2026 · 6 articles
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration (FDA) is the regulatory body responsible for approving the Lyme disease vaccine developed by Pfizer and Valneva SE. Its approval is essential for the vaccine to become available to the public.
Pfizer: Pfizer is a pharmaceutical company developing a new Lyme disease vaccine, which has shown 70-75% effectiveness in late-stage studies. The company plans to seek regulatory approval, which could significantly boost its market position in infectious disease prevention.
Apr 30, 2026 · 24 articles
Regulatory
United States — Food and Drug Administration: The FDA granted approval for the first mRNA flu vaccine, a regulatory milestone that validates the safety and efficacy of mRNA technology for seasonal influenza prevention.
Pfizer: Pfizer, a leader in mRNA COVID-19 vaccines, benefits from the broader acceptance of mRNA technology, though the specific flu vaccine approval is not attributed to them.
Aug 06, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA granted approval for mFLUSIVA, marking a regulatory milestone and demonstrating its role in vaccine oversight despite internal controversies.
Pfizer: Pfizer, a rival in mRNA vaccines, may face competitive pressure as Moderna expands its mRNA platform into flu.
Aug 05, 2026 · 105 articles
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration approved the RSVpreF vaccine in 2023, which is a prerequisite for its widespread use and impact on public health.
Pfizer: Pfizer manufactures the RSVpreF vaccine, which has shown significant effectiveness in preventing RSV-associated hospitalizations in infants. This positive real-world data validates their product and could lead to increased sales and market share in the vaccine segment.
Jun 05, 2026 · 7 articles
Tech
United States — Food and Drug Administration: The United States — Food and Drug Administration encourages the adoption of advanced manufacturing technologies and continuous production models, reinforcing the shift from reactive to proactive compliance strategies in the pharmaceutical industry.
Pfizer: Pfizer has implemented digital manufacturing programs that leverage AI and data-driven systems to improve efficiency and operational performance, demonstrating a broader industry commitment to intelligent manufacturing.
Apr 07, 2026 · 8 articles
Tech
United States — Food and Drug Administration: The FDA will review the trial data for potential approval. The companies plan to file for approval, and the vaccine could be available as soon as 2027 if approved.
Pfizer: Pfizer's COVID vaccine used BioNTech's mRNA technology, and the success of mRNA cancer vaccines could have indirect implications.
Aug 19, 2026 · 108 articles
Regulatory
United States — Food and Drug Administration: The FDA is mentioned in the context of a separate approval for Pfizer's Hympavzi, not directly related to this event.
Pfizer: Pfizer is the lead developer and would exclusively manufacture and commercialize the vaccine if approved. The EMA validation advances its pipeline and could provide a new revenue stream.
Aug 14, 2026 · 12 articles
Domestic
United States — Food and Drug Administration: Mentioned in context of vaccine authorization; not directly involved in the released texts.
Pfizer: One of the vaccine manufacturers; the controversy may slightly affect public perception, but no direct impact.
Aug 06, 2026 · 17 articles
Business
United States — Food and Drug Administration: The FDA approved Palsonify in 2025, enabling its commercial availability. The agency's regulatory decisions are relevant to the value of the acquired assets.
Pfizer: Competitor in acromegaly market; PALSONIFY may compete with its treatments.
Jul 06, 2026 · 34 articles
Business
United States — Food and Drug Administration: The FDA has cleared several of Ascentage Pharma's Phase III trials, but this event does not directly involve the FDA.
Pfizer: Pfizer is a partner of Ascentage Pharma, but this event does not directly involve Pfizer.
Jul 26, 2026 · 6 articles
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration classified the recall as Class II and is overseeing the process, ensuring patient safety and regulatory compliance.
Oct 29, 2025 · 8 articles
20
Pfizer received approval United States — Food and Drug AdministrationEMA validates...
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Pfizer interact across events, view sentiment trends, and discover connected entities.
Open Dashboard